PegInno ceased production in 2018, so it is currently not sold in China. PegIntron is an antiviral pet disease treatment drug developed by the German pharmaceutical company Roche. As an important antiviral drug, PegIntron is widely used to treat hepatitis C around the world.

China implements a strict management system for drugs. All imported drugs must be processed by the National Medical Products Administration (NMPA) of China. Only after registration and approval can you sell in China. However, due to factors such as drug prices and medical insurance policies, patients' choice and acceptance of drugs will also vary. Therefore, PegIntron’s sales in the Chinese market also need to consider the actual needs and acceptance of patients.